Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users

Don Des Jarlais, S. R. Friedman, M. Marmor, H. Cohen, D. Mildvan, S. Yancovitz, U. Mathur, W. El-Sadr, T. J. Spira, J. Garber, S. T. Beatrice, A. S. Abdul-Quader, J. L. Sotheran

Research output: Contribution to journalArticle

Abstract

A cohort of 334 intravenous (IV) drug users from New York City drug treatment programs were followed over a mean 9-month period. Among the 165 who were seropositive at enlistment, four developed clinical AIDS, for an annual rate of 3%. Elevated IgA was a significant predictor of developing AIDS. Among 72 subjects who were initially seronegative and who were re-interviewed, four were seropositive at follow-up, for a seroconversion rate of 7% per year among seronegatives. Among seropositive subjects who did not develop AIDS or fatal AIDS related complex (ARC), continued drug injection was associated with rate of T4 cell loss, and there was a non-significant trend for males to lose T4 cells more rapidly than females. While it was not possible to distinguish the mechanism underlying the relationship between continued drug injection and T4 cell loss, seropositive IV drug users should be warned that continued injection may lead to increased HIV-related immunosuppression as well as, if injection equipment is shared, risking viral transmission to others.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalAIDS
Volume1
Issue number2
StatePublished - Dec 1 1987

Fingerprint

HIV Seropositivity
CD4-Positive T-Lymphocytes
Drug Users
Acquired Immunodeficiency Syndrome
Injections
Pharmaceutical Preparations
AIDS-Related Complex
Immunosuppression
Immunoglobulin A
HIV
Equipment and Supplies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Des Jarlais, D., Friedman, S. R., Marmor, M., Cohen, H., Mildvan, D., Yancovitz, S., ... Sotheran, J. L. (1987). Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. AIDS, 1(2), 105-111.

Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. / Des Jarlais, Don; Friedman, S. R.; Marmor, M.; Cohen, H.; Mildvan, D.; Yancovitz, S.; Mathur, U.; El-Sadr, W.; Spira, T. J.; Garber, J.; Beatrice, S. T.; Abdul-Quader, A. S.; Sotheran, J. L.

In: AIDS, Vol. 1, No. 2, 01.12.1987, p. 105-111.

Research output: Contribution to journalArticle

Des Jarlais, D, Friedman, SR, Marmor, M, Cohen, H, Mildvan, D, Yancovitz, S, Mathur, U, El-Sadr, W, Spira, TJ, Garber, J, Beatrice, ST, Abdul-Quader, AS & Sotheran, JL 1987, 'Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users', AIDS, vol. 1, no. 2, pp. 105-111.
Des Jarlais D, Friedman SR, Marmor M, Cohen H, Mildvan D, Yancovitz S et al. Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. AIDS. 1987 Dec 1;1(2):105-111.
Des Jarlais, Don ; Friedman, S. R. ; Marmor, M. ; Cohen, H. ; Mildvan, D. ; Yancovitz, S. ; Mathur, U. ; El-Sadr, W. ; Spira, T. J. ; Garber, J. ; Beatrice, S. T. ; Abdul-Quader, A. S. ; Sotheran, J. L. / Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. In: AIDS. 1987 ; Vol. 1, No. 2. pp. 105-111.
@article{7b619cfea72748baa109074695407d21,
title = "Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users",
abstract = "A cohort of 334 intravenous (IV) drug users from New York City drug treatment programs were followed over a mean 9-month period. Among the 165 who were seropositive at enlistment, four developed clinical AIDS, for an annual rate of 3{\%}. Elevated IgA was a significant predictor of developing AIDS. Among 72 subjects who were initially seronegative and who were re-interviewed, four were seropositive at follow-up, for a seroconversion rate of 7{\%} per year among seronegatives. Among seropositive subjects who did not develop AIDS or fatal AIDS related complex (ARC), continued drug injection was associated with rate of T4 cell loss, and there was a non-significant trend for males to lose T4 cells more rapidly than females. While it was not possible to distinguish the mechanism underlying the relationship between continued drug injection and T4 cell loss, seropositive IV drug users should be warned that continued injection may lead to increased HIV-related immunosuppression as well as, if injection equipment is shared, risking viral transmission to others.",
author = "{Des Jarlais}, Don and Friedman, {S. R.} and M. Marmor and H. Cohen and D. Mildvan and S. Yancovitz and U. Mathur and W. El-Sadr and Spira, {T. J.} and J. Garber and Beatrice, {S. T.} and Abdul-Quader, {A. S.} and Sotheran, {J. L.}",
year = "1987",
month = "12",
day = "1",
language = "English (US)",
volume = "1",
pages = "105--111",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users

AU - Des Jarlais, Don

AU - Friedman, S. R.

AU - Marmor, M.

AU - Cohen, H.

AU - Mildvan, D.

AU - Yancovitz, S.

AU - Mathur, U.

AU - El-Sadr, W.

AU - Spira, T. J.

AU - Garber, J.

AU - Beatrice, S. T.

AU - Abdul-Quader, A. S.

AU - Sotheran, J. L.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - A cohort of 334 intravenous (IV) drug users from New York City drug treatment programs were followed over a mean 9-month period. Among the 165 who were seropositive at enlistment, four developed clinical AIDS, for an annual rate of 3%. Elevated IgA was a significant predictor of developing AIDS. Among 72 subjects who were initially seronegative and who were re-interviewed, four were seropositive at follow-up, for a seroconversion rate of 7% per year among seronegatives. Among seropositive subjects who did not develop AIDS or fatal AIDS related complex (ARC), continued drug injection was associated with rate of T4 cell loss, and there was a non-significant trend for males to lose T4 cells more rapidly than females. While it was not possible to distinguish the mechanism underlying the relationship between continued drug injection and T4 cell loss, seropositive IV drug users should be warned that continued injection may lead to increased HIV-related immunosuppression as well as, if injection equipment is shared, risking viral transmission to others.

AB - A cohort of 334 intravenous (IV) drug users from New York City drug treatment programs were followed over a mean 9-month period. Among the 165 who were seropositive at enlistment, four developed clinical AIDS, for an annual rate of 3%. Elevated IgA was a significant predictor of developing AIDS. Among 72 subjects who were initially seronegative and who were re-interviewed, four were seropositive at follow-up, for a seroconversion rate of 7% per year among seronegatives. Among seropositive subjects who did not develop AIDS or fatal AIDS related complex (ARC), continued drug injection was associated with rate of T4 cell loss, and there was a non-significant trend for males to lose T4 cells more rapidly than females. While it was not possible to distinguish the mechanism underlying the relationship between continued drug injection and T4 cell loss, seropositive IV drug users should be warned that continued injection may lead to increased HIV-related immunosuppression as well as, if injection equipment is shared, risking viral transmission to others.

UR - http://www.scopus.com/inward/record.url?scp=0023606883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023606883&partnerID=8YFLogxK

M3 - Article

C2 - 2896511

AN - SCOPUS:0023606883

VL - 1

SP - 105

EP - 111

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -